Compare Duke Energy Corp (DUK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Duke Energy Corp trades at $123.5 (market cap $96.05B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Duke Energy Corp pays a 3.52% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Duke Energy Corp nearer its low. Which is the better fit depends on your goals.
| DUK | XBI | |
|---|---|---|
Market Cap | $96.05B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $133.46 | $164.28 |
52-Week Low | $113.99 | $86.92 |
Enterprise Value | $188.56B | — |
Dividend Yield | 3.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $123.23, up 1.68% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $1.43 exceeding expectations, supported by growing revenue and healthy profit margins. Recent news highlights operational challenges from storms affecting customers but also strategic initiatives including a $35 million equity units offering and data center growth opportunities.
The outlook remains stable with analyst consensus pointing to upside potential (target $136.17) and no sell ratings. Key risks include regulatory scrutiny and capital expenditure pressures, but the company's dividend reliability and infrastructure investments provide long-term stability. The stock presents a balanced opportunity for income-focused investors amid current technical weakness.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
